GALNS and mucopolysaccharidosis: For instance, MSCs and their EVs have shown potential in treating corneal diseases caused by Mucopolysaccharidoses by delivering the enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS) to defective cells (Flanagan et al., 2021).